I sure agree with you about the BPs. A number of BPs have patents running out for major drugs. These BPs must be hungry and more likely than not, are currently engaged in a bidding war for CX-717 and perhaps even the pipeline, including the high impact ampakines. I think Cortex is in a great position and additional investment is a no-brainer.